尤瑞克林联合阿替普酶静脉溶栓对 急性脑梗死患者的临床疗效

Clinical Efficacy of Intravenous Thrombolysis with Urinary Kallidinogenase with Alteplase in Patients with Acute Cerebral Infarction

摘要:

〔摘 要〕 目的：探讨尤瑞克林联合阿替普酶静脉溶栓治疗急性脑梗死的临床疗效。方法：选择蓬莱市人民医院 2017 年 2 月至 2019 年 9 月间收治的 136 例急性脑梗死患者，随机分为观察组与对照组，每组 68 例。对照组给予常规阿替普酶静 脉溶栓治疗，观察组在对照组基础上加用尤瑞克林治疗，治疗后 3 个月对两组患者的综合疗效进行评价。结果：观察组患 者治疗后美国国立卫生研究院脑卒中量表（NIHSS）评分及 Barthel 指数（BI）评分均优于对照组，差异具有统计学意义 （P ＜ 0.05）。观察组患者治疗总有效率为 94.1 %，显著高于对照组的 82.4 %，差异具有统计学意义（P ＜ 0.05）。结论： 尤瑞克林联合阿替普酶静脉溶栓治疗急性脑梗死的疗效可靠。

Abstract:

〔Abstract〕 Objective To evaluate the clinical efficacy of urinary kallidinogenase combined with alteplase intravenous thrombolysis in the treatment of acute cerebral infarction. Methods 136 patients with acute cerebral infarction treated in Penglai people's Hospital from February 2017 to September 2019 were randomly divided into observation group and control group, with 68 cases in each group. The control group was given routine intravenous thrombolytic therapy with alteplase, and the observation group was treated with urecolin on the basis of the control group. The comprehensive curative effects of the two groups were evaluated 3 months after treatment. Results After treatment, the scores of NIHSS and Barthel Index (BI) in the observation group were better than those in the control group (P < 0.05). The improvement of neurological function and ADL in the observation group was better than that in the control group (P < 0.05). The total effective rate of the observation group was 94.1%, which was significantly higher than 82.4% of the control group (P < 0.05). Conclusion Urinary Kallidinogenase combined with alteplase intravenous thrombolysis is effective in the treatment of acute cerebral infarction.